Precision Medicine in Duchenne Muscular Dystrophy: A Deep Dive into Patient-Specific Genetic Corrections and Delivery Sy
The complexity of Duchenne Muscular Dystrophy (DMD) stems from the diverse array of mutations in the large dystrophin gene, necessitating precision medicine approaches tailored to the individual patient’s specific genetic fault. New therapies, including gene editing techniques and mutation-specific RNA-based treatments, aim to provide functional dystrophin protein, moving beyond mere symptom management.
A critical challenge in developing and delivering these advanced therapies involves finding safe and efficient vectors to transport the necessary genetic material to all affected skeletal and cardiac muscle tissues. Successfully overcoming these delivery hurdles is essential for realizing the full therapeutic promise of these innovative and life-changing genetic interventions for young patients.